Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease

Molecular Medicine Reports

Volumn 3, Issue 6, 2010, Pages 909-915

  Wang, Yugang ^a   Shi, Min ^a   Fu, Hongyi ^a   Xu, Hui ^a   Wei, Jue ^a   Wang, Ting ^a   Wang, Xinmin ^b  

^a Shanghai Changning Center Hospital   (China)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

High fat diet; Liver disease; Rapamycin; Rat model

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; INSULIN RESISTANCE; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; STEATOSIS;

ANIMALIA; MAMMALIA; RATTUS;

EID: 78649473370     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.365     Document Type: Article

References (42)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
2. Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923, 2003.
3. Chitturi S and Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21: 27-41, 2001.
4. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
5. Parkington JD, Siebert AP, LeBrasseur NK and Fielding RA: Differential activation of mTOR signaling by contractile activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 285: R1086-R1090, 2003.
6. Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R and Hall MN: TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 5: 105-118, 1994.
7. White MF: IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422, 2002.
8. Jansen PL: Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol 16: 1079-1085, 2004.
9. Kallwitz ER, McLachlan A and Cotler SJ: Role of peroxisome proliferator-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14: 22-28, 2008.
10. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
11. Adams LA, Angulo P and Lindor KD: Nonalcoholic fatty liver disease. CMAJ 172: 899-905, 2005.
12. Choudhury J and Sanyal AJ: Insulin resistance in NASH. Front Biosci 10: 1520-1533, 2005.
13. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L and Velagic V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550, 2007.
14. Valenti L, Fracanzani AL, Dongiovanni P, et al: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122: 274-280, 2002.
15. Morino S, Kondo T, Sasaki K, et al: Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling. PLoS ONE 3: e4068, 2008.
16. Tzatsos A and Kandror KV: Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76, 2006.
17. Greene MW and Garofalo RS: Positive and negative regulatory role of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) serine/threonine phosphorylation. Biochemistry 41: 7082-7091, 2002.
18. Ogawa W, Matozaki T and Kasuga M: Role of binding proteins to IRS-1 in insulin signalling. Mol Cell Biochem 182: 13-22, 1998.
19. White MF: The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182: 3-11, 1998.
20. Chen XL, Xia ZF, Ben DF, Wang GQ and Wei D: Role of p38 mitogen-activated protein kinase in lung injury after burn trauma. Shock 19: 475-479, 2003.
21. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
22. Harrington LS, Findlay GM and Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42, 2005.
23. Boura-Halfon S and Zick Y: Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296: E581-E591, 2009.
24. Um SH, D'Alessio D and Thomas G: Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3: 393-402, 2006.
25. Um SH, Frigerio F, Watanabe M, et al: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205, 2004.
26. Harrington LS, Findlay GM, Gray A, et al: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223, 2004.
27. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC and Rhodes CJ: Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 280: 2282-2293, 2005.
28. Di Paolo S, Teutonico A, Leogrande D, Capobianco C and Schena PF: Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 17: 2236-2244, 2006.
29. Shinohara M, Chung YJ, Saji M and Ringel MD: AKT in thyroid tumorigenesis and progression. Endocrinology 148: 942-947, 2007.
30. Polyzos SA, Kountouras J and Zavos C: Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9: 299-314, 2009.
31. Tsochatzis EA, Papatheodoridis GV and Archimandritis AJ: Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009: 831670, 2009.
32. Ishizuka K, Usui I, Kanatani Y, et al: Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology 148: 2994-3003, 2007.
33. Dogru T, Ercin CN, Erdem G, Sonmez A, Tapan S and Tasci I: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103: 3217-3218, 2008.
34. Poniachik J, Csendes A, Diaz JC, et al: Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 33: 252-257, 2006.
35. Matsuki T, Horai R, Sudo K and Iwakura Y: IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 198: 877-888, 2003.
36. Yen CJ, Izzo JG, Lee DF, et al: Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 68: 2632-2640, 2008.
37. Djavaheri-Mergny M, Amelotti M, Mathieu J, et al: NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy. J Biol Chem 281: 30373-30382, 2006.
38. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS: Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22: 1490-1500, 2008.
39. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F and Foti M: PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134: 268-280, 2008.
40. Aggarwal BB, Takada Y, Shishodia S, et al: Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42: 341-353, 2004.
41. Schwabe RF and Brenner DA: Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290: G583-G589, 2006.
42. Lee DF, Kuo HP, Chen CT, et al: IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455, 2007.